Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion type Assertion NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_head.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion description "[BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-?B.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_provenance.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion evidence source_evidence_literature NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_provenance.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion SIO_000772 22975686 NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_provenance.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion wasDerivedFrom befree-20140225 NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_provenance.
- NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_assertion wasGeneratedBy ECO_0000203 NP612069.RAvKgHln-BYf1I_5NV6TszmEPeGbhe7uPHr_2GzCks60M130_provenance.